A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial

Annals of Oncology

Volumn 11, Issue 10, 2000, Pages 1295-1300

  Rinaldi, M ^a   Crino L ^b   Scagliotti, G V ^c   Mosconi, A M ^d   De Marinis, F ^e   Gridelli, C ^f   Selvaggi, G ^c   Della Giulia, M ^a   Darwish, S ^d   Porrozzi, S ^d   Novello, S ^c   Cipri, A ^e   Bartolucci, R ^g   Calandri, C ^b   Tonato, M ^d  

^a Division of Medical Oncology   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Policlinico Hospital   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g S MARIA HOSPITAL   (Italy)

Author keywords

Advanced NSCLC; Cisplatin dose level; Gemcitabine cisplatin combination

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0033758715     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008334610955     Document Type: Article

References (22)

1. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Special article: Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer
3. New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: A review of the literature and future directions
4. Randomized phase III study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
5. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
6. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial
7. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
8. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian lung cancer project
9. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
10. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer
11. Phase I/II study of cisplatin in combination with gemcitabine in non-small-cell lung cancer
12. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC)
13. Gemcitabine plus cisplatin in non-small-cell lung cancer: A phase II study
14. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer (NSCLC)
15. Synergistic interaction between cisplatin and gemcitabine in vitro
16. Interaction between cisplatin and gemcitabine in vitro and in vivo
17. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
18. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma
19. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
20. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules
21. Optimal two-stage designs for phase II clinical trials